Top 5 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital

Page 5 of 5

1. Graphite Bio, Inc. (NASDAQ:GRPH)

Samsara BioCapital’s Stake Value: $121.8 million

Percentage of Samsara BioCapital’s 13F Portfolio: 19.11%

Number of Hedge Fund Holders: 16

Graphite Bio, Inc. (NASDAQ:GRPH) operates as a clinical-stage gene-editing company. The company was previously known as Integral Medicines, Inc. till August 2020. With precision gene correction, the firm aims to cure and treat a number of life-threatening diseases like sickle cell disease, X-linked severe combined immunodeficiency syndrome, and Gaucher disease.

Out of the 867 hedge funds tracked by Insider Monkey, 16 funds held stakes in Graphite Bio, Inc. (NASDAQ:GRPH) worth $321.66 million in the third quarter of the year, down from 22 funds holding stakes worth $623.03 million in the preceding quarter.

According to the filings of the third quarter of 2021, Samsara BioCapital’s largest holding is Graphite Bio, Inc. (NASDAQ:GRPH) with 7.43 million shares worth $121.8 million, representing 19.11% of the hedge fund’s portfolio.

You can also take a peek at Billionaire Israel Englander is Buying These 10 Stocks and 10 Value Stocks to Buy According to Billionaire Paul Tudor Jones.

Page 5 of 5